{
    "ticker": "ITCI",
    "name": "Intra-Cellular Therapies, Inc.",
    "description": "Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for neuropsychiatric diseases. Founded in 2002 and headquartered in New York City, the company is dedicated to addressing the unmet medical needs of patients suffering from serious mental health disorders. Intra-Cellular Therapies is best known for its lead product, Caplyta (lumateperone), which is approved for the treatment of schizophrenia and bipolar depression. Caplyta represents a novel therapeutic mechanism that modulates multiple neurotransmitter systems, aiming to provide effective symptom relief with a favorable side effect profile. The company is also actively engaged in advancing its pipeline of product candidates targeting other central nervous system disorders, including major depressive disorder and neurodegenerative diseases. With a strong commitment to research and development, Intra-Cellular Therapies seeks to leverage its expertise in neurobiology to bring transformative therapies to market. The company collaborates with academic institutions and research organizations to further its understanding of complex brain disorders, ultimately striving to improve the quality of life for patients and their families.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York City, New York, USA",
    "founded": "2002",
    "website": "https://www.intracellulartherapies.com",
    "ceo": "Dr. Sharon Mates",
    "social_media": {
        "twitter": "https://twitter.com/IntracellularT",
        "linkedin": "https://www.linkedin.com/company/intra-cellular-therapies/"
    },
    "investor_relations": "https://investors.intracellulartherapies.com",
    "key_executives": [
        {
            "name": "Dr. Sharon Mates",
            "position": "CEO"
        },
        {
            "name": "Dr. David S. O'Connell",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Approved Therapies",
            "products": [
                "Caplyta"
            ]
        },
        {
            "category": "Pipeline Candidates",
            "products": [
                "ITI-007",
                "ITI-214"
            ]
        }
    ],
    "seo": {
        "meta_title": "Intra-Cellular Therapies, Inc. | Innovative Neuropsychiatric Treatments",
        "meta_description": "Explore Intra-Cellular Therapies, Inc., a leader in biopharmaceuticals focused on neuropsychiatric diseases. Discover our innovative therapies and commitment to mental health.",
        "keywords": [
            "Intra-Cellular Therapies",
            "Caplyta",
            "neuropsychiatric diseases",
            "schizophrenia",
            "bipolar depression",
            "biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Intra-Cellular Therapies known for?",
            "answer": "Intra-Cellular Therapies is known for developing Caplyta, a treatment for schizophrenia and bipolar depression."
        },
        {
            "question": "Who is the CEO of Intra-Cellular Therapies?",
            "answer": "Dr. Sharon Mates is the CEO of Intra-Cellular Therapies, Inc."
        },
        {
            "question": "Where is Intra-Cellular Therapies headquartered?",
            "answer": "Intra-Cellular Therapies is headquartered in New York City, New York, USA."
        },
        {
            "question": "What are the main products of Intra-Cellular Therapies?",
            "answer": "The main product is Caplyta, with additional candidates in development."
        },
        {
            "question": "When was Intra-Cellular Therapies founded?",
            "answer": "Intra-Cellular Therapies was founded in 2002."
        }
    ],
    "competitors": [
        "AXON",
        "VRNA",
        "PTON"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "ABBV"
    ]
}